Investor News / RNS

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has been recognised by the French Ministry of Higher Education and Research as an eligible research organisation for French companies seeking to claim French Research and Development tax credits (“Agrément crédit d’impôt recherche") on their research projects (2012 to 2014). Read more...

Read More

Chairman’s Statement   Summary of Results in the year ended 30 June 2012   Fundraising in April 2012 generated cash of £555,000 before issue expenses. The turnover of the Company more than doubled to £135,306 (2011: £53,345). The operating loss reduced to £577,922 (2011: £693,795). On 30 June 2012 the surplus of shareholders’ funds was £734,570 (2011: £755,511). With a now fully validated Virtual Tumour technology, Physiomics has concentrated...

Read More

The Company announces that it has raised £555,000 from the issue of 370,000,000 new ordinary shares of 0.04p each ("Ordinary Shares") at a price of 0.15p per share, by way of a placing through WH Ireland Limited (the "Placing"). Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 2 May 2012...

Read More

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it will be participating in the AACR Annual Meeting 2012, taking place at the McCormick Place West, Chicago, Illinois on March 31- April 4 2012.  Dr Frances Brightman, Senior Scientist at Physiomics, will present the application of the Virtual Tumour platform to three-dimensional cell cultures...

Read More

The Board of Physiomics Plc (AIM: PYC), a UK-based systems biology company, today announces the financial results for the six months ended 31 December 2011. Physiomics Plc is a computational systems biology services company, applying simulations supporting pharmaceutical decision making throughout the entire drug discovery process, particularly for cancer therapies. Read more...

Read More

Physiomics plc (AIM: PYC), the Oxford, UK-based systems biology company, is pleased to announce its intention to increase the scope of its offering through the development of a new modelling service to predict the cardiac toxicity of drugs.  The Directors believe that this new service will be of particular interest to biotechnology companies looking to streamline their drug discovery programmes and improve the success rates...

Read More

  The below excerpt has been taken from InSphero’s latest newsletter, 'Upgrade Your Cell-Based Assays to 3D', discussing the collaboration between InSphero and Physiomics plc. Customer case study: 3D microtissue growth and drug response – virtual and in vitro models InSphero’s customer Physiomics plc develops computational systems-biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. The Oxford (UK)-based company has created detailed...

Read More

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it will be participating in the EORTC-NCI-AACR symposium on “Molecular Targets and Cancer Therapeutics”, taking place at the Moscone Center West, San Francisco, California on 12-16 November 2011. Dr Eric Fernandez, Project Leader at Physiomics, will present on a prototype version of an anti-cancer drug combination and regimen database. Dr...

Read More